{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:47:00Z","timestamp":1782398820632,"version":"3.54.5"},"reference-count":100,"publisher":"Croatian Society for Medical Biochemistry and Laboratory Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochem. med. (Online)"],"published-print":{"date-parts":[[2026,6,15]]},"abstract":"<jats:p>Myelodysplastic neoplasms (MDS) are clonal hematopoietic disorders defined by ineffective hematopoiesis, cytopenias, and variable risk of progression to acute myeloid leukemia. Although genomic and epigenomic studies have provided insight into disease pathogenesis, reliable biomarkers for diagnosis and prognosis remain limited. Proteomics offers an important advantage because it reflects the functional protein state and captures post-translational modifications, making it highly relevant for risk assessment and therapy guidance. Recent studies have identified several groups of candidate biomarkers. Kinases and signal transduction proteins such as CAMK1D, PRKCZ, KIT, MAST4, PAK6, PTK7, and NTRK1 are dysregulated in MDS and associated with poor outcomes, immune evasion, and aberrant stem cell signaling. Oncofetal proteins like IGF2BP3 and signaling regulators such as RBP4 further highlight proteomic signatures linked to chemoresistance and subtype specificity. In the transplant setting, immune regulators including CSK, FGR, CRTAM, GP1BA, UBE2N, and STAT1 may serve as predictors of graft rejection and relapse. Cytoskeletal and extracellular matrix proteins such as CEP55, Talin-1, Kindlin-3, Vinculin, THBS1, LRG1, SPARC, SAA1, Clusterin, and PRDM16 underscore the role of bone marrow microenvironmental remodeling and adhesion defects in disease progression. Finally, metabolic enzymes such as LDHA reflect altered energy metabolism and correlate with more aggressive disease biology. Collectively, these proteomic candidates illustrate the complex interplay of signaling, immune regulation, bone microenvironment, and metabolism in MDS. Their validation in clinical cohorts could enable early detection, refined risk stratification, and new therapeutic avenues, positioning proteomics as a central tool in the future management of MDS.<\/jats:p>","DOI":"10.11613\/bm.2026.020504","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:41:29Z","timestamp":1781163689000},"page":"228-243","source":"Crossref","is-referenced-by-count":0,"title":["Proteomics in myelodysplastic syndromes"],"prefix":"10.11613","volume":"36","author":[{"given":"Ru\u0111er","family":"Novak","sequence":"first","affiliation":[{"name":"Centre for translational and clinical research, Department of Proteomics, School of Medicine, University of Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Mandac Smoljanovi\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology, Clinical Hospital Merkur, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovorka","family":"Grgurevi\u0107","sequence":"additional","affiliation":[{"name":"Centre for translational and clinical research, Department of Proteomics, School of Medicine, University of Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4885","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"key20260611074123_r1","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"key":"key20260611074123_r2","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/aje\/kwp074","article-title":"Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort.","volume":"169","author":"Ma","year":"2009","journal-title":"Am J Epidemiol"},{"key":"key20260611074123_r3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","article-title":"Inflammatory mechanisms in obesity.","volume":"29","author":"Gregor","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"key20260611074123_r4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/joim.12718","article-title":"Clinical implications of bone marrow adiposity.","volume":"283","author":"Veldhuis-Vlug","year":"2018","journal-title":"J Intern Med"},{"key":"key20260611074123_r5","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.1200\/JCO.2016.34.15_suppl.7064","article-title":"Risk of myelodysplasia in patients post solid organ transplant: A review of recent trends from a tertiary transplantation center.","volume":"34","author":"Konde","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20260611074123_r6","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamaoncol.2016.6435","article-title":"Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia.","volume":"3","author":"Ertz-Archambault","year":"2017","journal-title":"JAMA Oncol"},{"key":"key20260611074123_r7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beha.2019.02.007","article-title":"Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome.","volume":"32","author":"Chua","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"key20260611074123_r8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/flgastro-2012-100276","article-title":"Azathioprine-associated myelodysplastic syndrome in two patients with ulcerative colitis.","volume":"4","author":"Ahmad","year":"2013","journal-title":"Frontline Gastroenterol"},{"key":"key20260611074123_r9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5045\/br.2014.49.4.216","article-title":"Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.","volume":"49","author":"Visconte","year":"2014","journal-title":"Blood Res"},{"key":"key20260611074123_r10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: From clonal haematopoiesis to secondary leukaemia.","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"key20260611074123_r11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.semcancer.2017.07.009","article-title":"Epigenetics in myelodysplastic syndromes.","volume":"51","author":"Heuser","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"key20260611074123_r12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2014.01.001","article-title":"Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.","volume":"26","author":"Itzykson","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"key20260611074123_r13","first-page":"300","article-title":"Diagnosis of myelodysplastic syndromes: the classic and the novel.","volume":"110","author":"Oster","year":"2025","journal-title":"Haematologica"},{"key":"key20260611074123_r14","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2013-09-381665","article-title":"The genetic basis of myelodysplasia and its clinical relevance.","volume":"122","author":"Cazzola","year":"2013","journal-title":"Blood"},{"key":"key20260611074123_r15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12185-025-04038-5","article-title":"ASXL1 mutation-related clonal hematopoiesis and age-related diseases: clinical evidence and molecular insights.","volume":"122","author":"Sato","year":"2025","journal-title":"Int J Hematol"},{"key":"key20260611074123_r16","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180065","article-title":"Clonal hematopoiesis and hematological malignancy.","volume":"134","author":"Dunn","year":"2024","journal-title":"J Clin Invest"},{"key":"key20260611074123_r17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/asheducation-2017.1.73","article-title":"Aging, hematopoiesis, and the myelodysplastic syndromes.","volume":"2017","author":"Chung","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key20260611074123_r18","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.5045\/br.2021.2021010","article-title":"Myelodysplastic syndromes and overlap syndromes.","volume":"56","author":"Chang","year":"2021","journal-title":"Blood Res"},{"key":"key20260611074123_r19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/hematolrep15010008","article-title":"JAK2 Mutations Are Rare and Diverse in Myelodysplastic Syndromes: Case Series and Review of the Literature.","volume":"15","author":"Delio","year":"2023","journal-title":"Hematol Rep"},{"key":"key20260611074123_r20","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1038\/s41467-025-60884-1","article-title":"JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.","volume":"16","author":"Maslah","year":"2025","journal-title":"Nat Commun"},{"key":"key20260611074123_r21","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1038\/s41375-021-01265-7","article-title":"Current challenges and unmet medical needs in myelodysplastic syndromes.","volume":"35","author":"Platzbecker","year":"2021","journal-title":"Leukemia"},{"key":"key20260611074123_r22"},{"key":"key20260611074123_r23","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"key20260611074123_r24","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes.","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"key":"key20260611074123_r25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"key20260611074123_r26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000489042","article-title":"ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.","volume":"86","author":"Valent","year":"2019","journal-title":"Pathobiology"},{"key":"key20260611074123_r27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood-2018-10-844670","article-title":"MDS overlap disorders and diagnostic boundaries.","volume":"133","author":"Tanaka","year":"2019","journal-title":"Blood"},{"key":"key20260611074123_r28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/asheducation-2015.1.299","article-title":"The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).","volume":"2015","author":"Malcovati","year":"2015","journal-title":"Hematology."},{"key":"key20260611074123_r29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.24930","article-title":"Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.","volume":"93","author":"Montalban-Bravo","year":"2018","journal-title":"Am J Hematol"},{"key":"key20260611074123_r30","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for Myelodysplastic Syndromes.","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"key20260611074123_r31","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evidence"},{"key":"key20260611074123_r32","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.","volume":"39","author":"Nakamura","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20260611074123_r33","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20260611074123_r34","doi-asserted-by":"crossref","first-page":"921.e1","DOI":"10.1016\/j.jtct.2021.08.007","article-title":"Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.","volume":"27","author":"Oran","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"key20260611074123_r35","first-page":"300","article-title":"Diagnosis of myelodysplastic syndromes: the classic and the novel.","volume":"110","author":"Oster","year":"2025","journal-title":"Haematologica"},{"key":"key20260611074123_r36","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2021.719010","article-title":"Stem Cells in the Myelodysplastic Syndromes.","volume":"2","author":"Zhan","year":"2021","journal-title":"Front Aging"},{"key":"key20260611074123_r37","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3390\/cancers13071610","article-title":"Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).","volume":"13","author":"Bewersdorf","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20260611074123_r38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2019-126271","article-title":"The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results.","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"key20260611074123_r39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2025","article-title":"CD99 is a therapeutic target on disease stem cells in myeloid malignancies.","volume":"9","author":"Chung","year":"2017","journal-title":"Sci Transl Med"},{"key":"key20260611074123_r40","doi-asserted-by":"crossref","first-page":"10105","DOI":"10.3390\/ijms221810105","article-title":"Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.","volume":"22","author":"Cluzeau","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20260611074123_r41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/curroncol32060319","article-title":"Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS).","volume":"32","author":"Berg","year":"2025","journal-title":"Curr Oncol"},{"key":"key20260611074123_r42","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/bloodadvances.2023011512","article-title":"Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes.","volume":"8","author":"Yao","year":"2024","journal-title":"Blood Adv"},{"key":"key20260611074123_r43","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.833068","article-title":"Global Proteomics Analysis of Bone Marrow: Establishing Talin-1 and Centrosomal Protein of 55 kDa as Potential Molecular Signatures for Myelodysplastic Syndromes.","volume":"12","author":"Moura","year":"2022","journal-title":"Front Oncol"},{"key":"key20260611074123_r44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3233\/CBM-210033","article-title":"Mass spectrometry, data re-analysis, and homology modelling predict posttranslational modifications of leucine-rich alpha-2-glycoprotein as a marker of myelodysplastic syndrome.","volume":"34","author":"Majek","year":"2022","journal-title":"Cancer Biomark"},{"key":"key20260611074123_r45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262484","article-title":"Proteome changes of plasma-derived extracellular vesicles in patients with myelodysplastic syndrome.","volume":"17","author":"Pecankova","year":"2022","journal-title":"PLoS One"},{"key":"key20260611074123_r46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-023-00550-0","article-title":"Proteomics to predict relapse in patients with myelodysplastic neoplasms undergoing allogeneic hematopoietic cell transplantation.","volume":"12","author":"Guru Murthy","year":"2024","journal-title":"Biomark Res"},{"key":"key20260611074123_r47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3389\/fphar.2020.00443","article-title":"Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.","volume":"11","author":"Piris-Villaespesa","year":"2020","journal-title":"Front Pharmacol"},{"key":"key20260611074123_r48","article-title":"A review of NTRK fusions in cancer.","volume":"79","author":"Manea","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"key20260611074123_r49","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.474","article-title":"Calcium\/calmodulin-dependent kinase kinase 2 regulates hematopoietic stem and progenitor cell regeneration.","volume":"8","author":"Racioppi","year":"2017","journal-title":"Cell Death Dis"},{"key":"key20260611074123_r50","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1182\/blood-2011-01-333476","article-title":"Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool.","volume":"117","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"key20260611074123_r51","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy.","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260611074123_r52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/bloodadvances.2023011132","article-title":"Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia.","volume":"8","author":"Lin","year":"2024","journal-title":"Blood Adv"},{"key":"key20260611074123_r53","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.659977","article-title":"Biological Functions of RBP4 and Its Relevance for Human Diseases.","volume":"12","author":"Steinhoff","year":"2021","journal-title":"Front Physiol"},{"key":"key20260611074123_r54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113856","article-title":"Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development.","volume":"226","author":"Kim","year":"2021","journal-title":"Eur J Med Chem"},{"key":"key20260611074123_r55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-5956-10-31","article-title":"Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome.","volume":"10","author":"M\u00e1jek","year":"2012","journal-title":"Proteome Sci"},{"key":"key20260611074123_r56","doi-asserted-by":"crossref","first-page":"17600","DOI":"10.3390\/ijms242417600","article-title":"An Update on Protein Kinases as Therapeutic Targets\u2014Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.","volume":"24","author":"Silnitsky","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20260611074123_r57","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-20-3757","article-title":"First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.","volume":"27","author":"Maitland","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20260611074123_r58","doi-asserted-by":"crossref","first-page":"6784","DOI":"10.1021\/acs.jmedchem.9b01803","article-title":"Discovery of Highly Selective Inhibitors of Calmodulin-Dependent Kinases That Restore Insulin Sensitivity in the Diet-Induced Obesity in Vivo Mouse Model.","volume":"63","author":"Fromont","year":"2020","journal-title":"J Med Chem"},{"key":"key20260611074123_r59","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1124\/mol.115.099457","article-title":"Protein Kinase C (PKC)\u03b6 pseudosubstrate inhibitor peptide promiscuously binds PKC family isoforms and disrupts conventional PKC targeting and translocation.","volume":"88","author":"Bogard","year":"2015","journal-title":"Mol Pharmacol"},{"key":"key20260611074123_r60","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3390\/biomedicines13071652","article-title":"Advances and Challenges in Targeted Therapy and Its Combination Strategies for Leukemia.","volume":"13","author":"Zhong","year":"2025","journal-title":"Biomedicines"},{"key":"key20260611074123_r61","article-title":"Substrate and Inhibitor Specificity of the Type II p21-Activated Kinase, PAK6.","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One"},{"key":"key20260611074123_r62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI11830","article-title":"NF-kappaB: a key role in inflammatory diseases.","volume":"107","author":"Tak","year":"2001","journal-title":"J Clin Invest"},{"key":"key20260611074123_r63","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.molimm.2004.04.010","article-title":"Src-family kinases: rheostats of immune cell signaling.","volume":"41","author":"Lowell","year":"2004","journal-title":"Mol Immunol"},{"key":"key20260611074123_r64","doi-asserted-by":"crossref","first-page":"15885","DOI":"10.1016\/S0021-9258(17)40763-0","article-title":"Regulation of c-Fgr protein kinase by c-Src kinase (CSK) and by polycationic effectors.","volume":"269","author":"Ruzzene","year":"1994","journal-title":"J Biol Chem"},{"key":"key20260611074123_r65","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.str.2022.08.008","article-title":"ATP-site inhibitors induce unique conformations of the acute myeloid leukemia-associated Src-family kinase, Fgr.","volume":"30","author":"Du","year":"2022","journal-title":"Structure"},{"key":"key20260611074123_r66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/jpet.112.192187","article-title":"The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.","volume":"342","author":"Ochman","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"key20260611074123_r67","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.dnarep.2010.09.011","article-title":"The ubiquitous role of ubiquitin in the DNA damage response.","volume":"9","author":"Al-Hakim","year":"2010","journal-title":"DNA Repair (Amst)"},{"key":"key20260611074123_r68","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.stem.2021.01.011","article-title":"Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets.","volume":"28","author":"Wang","year":"2021","journal-title":"Cell Stem Cell"},{"key":"key20260611074123_r69","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention.","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"key20260611074123_r70","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"key20260611074123_r71","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial.","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"key20260611074123_r72","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial.","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20260611074123_r73","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.clml.2022.01.012","article-title":"A phase 1\/2 study of the oral Janus kinase 1 inhibitors INCB052793 and itacitinib alone or in combination with standard therapies for advanced hematologic malignancies.","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20260611074123_r74","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb7695","article-title":"Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia.","volume":"14","author":"Barreyro","year":"2022","journal-title":"Sci Transl Med"},{"key":"key20260611074123_r75","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.2021015162","article-title":"Inflammation and myeloid malignancy: quenching the flame.","volume":"140","author":"Stubbins","year":"2022","journal-title":"Blood"},{"key":"key20260611074123_r76","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103920","article-title":"The roles of S100A8\/A9 and S100A12 in autoimmune diseases: mechanisms, biomarkers, and therapeutic potential.","volume":"24","author":"Wang","year":"2025","journal-title":"Autoimmun Rev"},{"key":"key20260611074123_r77","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/nyas.13984","article-title":"Targeting LOX-1 in atherosclerosis and vasculopathy: current knowledge and future perspectives.","volume":"1443","author":"Tian","year":"2019","journal-title":"Ann N Y Acad Sci"},{"key":"key20260611074123_r78","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001496","article-title":"SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.","volume":"9","author":"Redin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"key20260611074123_r79","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1042\/BST20253017","article-title":"New molecular targets in acute leukemias: cytoskeletal regulatory proteins.","volume":"53","author":"Machado-Neto","year":"2025","journal-title":"Biochem Soc Trans"},{"key":"key20260611074123_r80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2020.151086","article-title":"Centrosomal protein 55: a new paradigm in tumorigenesis.","volume":"99","author":"Tandon","year":"2020","journal-title":"Eur J Cell Biol"},{"key":"key20260611074123_r81","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2023.106490","article-title":"Talin mechanotransduction in disease.","volume":"166","author":"Wang","year":"2024","journal-title":"Int J Biochem Cell Biol"},{"key":"key20260611074123_r82","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2009-08-238709","article-title":"Two mutations in the KINDLIN3 gene of a new leukocyte adhesion deficiency III patient reveal distinct effects on leukocyte function in vitro.","volume":"115","author":"McDowall","year":"2010","journal-title":"Blood"},{"key":"key20260611074123_r83","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtha.2023.10.013","article-title":"A novel leukocyte adhesion deficiency type III mutation manifests functional importance of the compact FERM domain in kindlin-3.","volume":"22","author":"Xu","year":"2024","journal-title":"J Thromb Haemost"},{"key":"key20260611074123_r84","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/872983","article-title":"Peripheral blood mononuclear cell proteome changes in patients with myelodysplastic syndrome.","volume":"2015","author":"Pecankova","year":"2015","journal-title":"BioMed Res Int"},{"key":"key20260611074123_r85","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood.V114.22.598.598","article-title":"Platelets derived from patients with myelodysplastic syndromes (MDS) show defective platelet aggregation and integrin \u03b1IIb\u03b23 receptor (GPIIb\/IIIa) signaling caused by a reduced expression of proteins required for inside-out signaling.","volume":"114","author":"Czibere","year":"2009","journal-title":"Blood"},{"key":"key20260611074123_r86","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1089\/ars.2009.2548","article-title":"Nitroproteomics of peripheral blood mononuclear cells from patients and a rat model of ALS.","volume":"11","author":"Nardo","year":"2009","journal-title":"Antioxid Redox Signal"},{"key":"key20260611074123_r87","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/35099066","article-title":"Transmembrane extracellular matrix-cytoskeleton crosstalk.","volume":"2","author":"Geiger","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20260611074123_r88","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3389\/fonc.2019.01567","article-title":"THBS1 is a novel serum prognostic factor of acute myeloid leukemia.","volume":"9","author":"Zhu","year":"2020","journal-title":"Front Oncol"},{"key":"key20260611074123_r89","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4274\/tjh.galenos.2022.2022.0290","article-title":"Proteomic case studies of MDS in progression: heterogeneity and more heterogeneity.","volume":"39","author":"Pecankova","year":"2022","journal-title":"Turk J Haematol"},{"key":"key20260611074123_r90","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08918.x","article-title":"PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.","volume":"156","author":"Duhoux","year":"2012","journal-title":"Br J Haematol"},{"key":"key20260611074123_r91","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13073","article-title":"Extracellular matrix remodeling effects of serum amyloid A1 in the human amnion: implications for fetal membrane rupture.","volume":"81","author":"Wang","year":"2019","journal-title":"Am J Reprod Immunol"},{"key":"key20260611074123_r92","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1182\/blood-2023-174485","article-title":"Serum amyloid A1 (SAA1) secreted by the stromal microenvironment drives malignant clonal proliferation in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).","volume":"142","author":"Chernak","year":"2023","journal-title":"Blood"},{"key":"key20260611074123_r93","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/14397595.2018.1515145","article-title":"AA amyloidosis - benefits and prospects of IL-6 inhibitors.","volume":"29","author":"Okuda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"key20260611074123_r94","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1021\/acsmedchemlett.1c00456","article-title":"Small peptides for inhibiting serum amyloid A aggregation.","volume":"12","author":"Jana","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"key20260611074123_r95","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/cells13080665","article-title":"Therapeutic potential of clusterin inhibition in human cancer.","volume":"13","author":"Mart\u00edn-Garc\u00eda","year":"2024","journal-title":"Cells"},{"key":"key20260611074123_r96","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202000264","article-title":"High-throughput, in-depth and estimated absolute quantification of plasma proteome using data-independent acquisition\/mass spectrometry (\u201cHIAP-DIA\u201d).","volume":"21","author":"Zhou","year":"2021","journal-title":"Proteomics"},{"key":"key20260611074123_r97","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"key20260611074123_r98","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1275000","article-title":"Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases.","volume":"14","author":"Han","year":"2023","journal-title":"Front Pharmacol"},{"key":"key20260611074123_r99","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.752118","article-title":"Galloflavin relieves the malignant behavior of colorectal cancer cells in the inflammatory tumor microenvironment.","volume":"12","author":"Guo","year":"2021","journal-title":"Front Pharmacol"},{"key":"key20260611074123_r100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11306-014-0672-8","article-title":"Metabolic consequences of LDHA inhibition by epigallocatechin gallate and oxamate in MIA PaCa-2 pancreatic cancer cells.","volume":"11","author":"Lu","year":"2015","journal-title":"Metabolomics"}],"container-title":["Biochemia medica"],"original-title":[],"link":[{"URL":"https:\/\/www.biochemia-medica.com\/assets\/images\/upload\/xml_tif\/bm-36-2-020504.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:55:57Z","timestamp":1782395757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biochemia-medica.com\/en\/journal\/36\/2\/10.11613\/BM.2026.020504"}},"subtitle":["towards novel prognostic and diagnostic biomarkers"],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":100,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,24]]},"published-print":{"date-parts":[[2026,6,15]]}},"URL":"https:\/\/doi.org\/10.11613\/bm.2026.020504","relation":{},"ISSN":["1846-7482","1330-0962"],"issn-type":[{"value":"1846-7482","type":"electronic"},{"value":"1330-0962","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,15]]}}}